Advertisement
Advertisement
ELUT
Elutia Inc. Class A Common Stock
0.99
USDSponsored
+0.05
+4.83%
Feb 06, 15:59 UTC -5
Closed
After-Market
1.01
+0.02
+1.82%
ELUT Earnings Reports
Positive Surprise Ratio
ELUT beat 7 of 21 last estimates.
33%
Next Report
Date of Next Report
Mar 04, 2026
Estimate for Q4 25 (Revenue/ EPS)
$3.47M
/-$0.11
Implied change from Q3 25 (Revenue/ EPS)
+4.36%
/+22.22%
Implied change from Q4 24 (Revenue/ EPS)
-36.58%
/-57.69%
Elutia Inc. Class A Common Stock earnings per share and revenue
On Nov 09, 2025, ELUT reported earnings of -0.09 USD per share (EPS) for Q3 25, beating the estimate of -0.15 USD, resulting in a 43.07% surprise. Revenue reached 3.32 million, compared to an expected 6.78 million, with a -51.01% difference. The market reacted with a -3.70% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 4 analysts forecast an EPS of -0.11 USD, with revenue projected to reach 3.47 million USD, implying an increase of 22.22% EPS, and increase of 4.36% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
AYTU BioPharma, Inc. Common Stock
Report Date
Feb 03, 2026 For Q2 26
Estimate
-$0.61
Actual
-$1.05
Surprise
-71.57%
Amgen Inc
Report Date
Feb 03, 2026 For Q4 25
Estimate
$4.82
Actual
$5.29
Surprise
+9.56%
Bristol-Myers Squibb Co.
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.12
Actual
$1.26
Surprise
+11.88%
GSK plc - ADR
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.23
Actual
$0.49
Surprise
+111.36%
Biogen Inc. Common Stock
Report Date
Feb 06, 2026 For Q4 25
Estimate
$1.62
Actual
$1.99
Surprise
+22.39%
Illumina Inc
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.24
Actual
$1.35
Surprise
+8.01%
QIAGEN N.V.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.64
Actual
$0.62
Surprise
-3.32%
Arrowhead Research Corporation
Report Date
Feb 05, 2026 For Q1 26
Estimate
$0.25
Actual
$0.22
Surprise
-14.76%
Bio-Techne Corp.
Report Date
Feb 04, 2026 For Q2 26
Estimate
$0.44
Actual
$0.46
Surprise
+3.95%
Immunovant, Inc. Common Stock
Report Date
Feb 06, 2026 For Q3 26
Estimate
-$0.72
Actual
-$0.61
Surprise
+16.27%
FAQ
What were Elutia Inc. Class A Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Elutia Inc. Class A Common Stock reported EPS of -$0.09, beating estimates by 43.07%, and revenue of $3.32M, -51.01% below expectations.
How did the market react to Elutia Inc. Class A Common Stock's Q3 2025 earnings?
The stock price moved down -3.7%, changed from $0.90 before the earnings release to $0.86 the day after.
When is Elutia Inc. Class A Common Stock expected to report next?
The next earning report is scheduled for Mar 04, 2026.
What are the forecasts for Elutia Inc. Class A Common Stock's next earnings report?
Based on 4
analysts, Elutia Inc. Class A Common Stock is expected to report EPS of -$0.11 and revenue of $3.47M for Q4 2025.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement